Table 1 Literature review of studies relating to HER3 prognostics in human breast cancer
Publication by | Laboratory Methodology | Cohort Characteristics | Prognostic Implications |
|---|---|---|---|
Takada et al. [91] | IHC (RTJ2) | met-HER2+ BCA (n = 29), TPD | ↓ Low HER3 expression was associated with shortened PFS |
Adamczyk et al. [25] | IHC (SP71) | HER2+ BCA (n = 97), Adj.T | ↑ High HER3 expression (only with concurrent PTEN negativity) was associated with shorten MFS |
Duchnowska et al. [44] | VeraTag assay | HER2+ BCA (n = 189), Adj.T | - No correlation between HER3 expression and OS in advanced stage HER2 + BCA |
Nishimura et al. [54] | VeraTag assay | met-HER2+ BCA (n = 47), T | - HER3 expression did not has any influence on PFS in trastuzumab-refractory advanced HER2 + BCA |
Koutras et al. [39] | qRT-PCR | BCA (n = 663, HER2 + BCA n = 143) | ↓ Low HER3 mRNA (only with concurrently high EGFR, high HER2, low HER4 mRNA) was associated with worse DFS |
Baselga et al. [38] | qRT-PCR*, IHC** (DAK-H3-IC) | HER2+ BCA (n = 740*/497**), Adj.T | ↓ High HER3 mRNA was associated with better prognosis in metastatic HER2 + BCA |
Berghoff et al. [16] | IHC (DAK-H3-IC) | met-BCA (n = 110, met-HER2 + BCA n = 34) | ↑ High HER3 expression was associated with shorter OS in initially metastatic HER2 + BCA subgroup |
Park et al. [31] | IHC (DAK-H3-IC) | met-HER2+ BCA (n = 125), T | ↑ High HER3 expression was associated with worse PFS in initially metastatic HER2 + BCA |
Bae et al. [26] | IHC (DAK-H3-IC) | HR-BCA (n = 886, HER2 + BCA n = 221) | ↑ High HER3 expression was associated with poorer DFS in HER2 + BCA subgroup and poorer DFS and OS in TNBC |
Czopek et al. [48] | IHC (DAK-H3-IC) | HER2+ BCA (n = 35) | - No correlation between HER3 expression and DFS or OS |
Lipton et al. [29] | VeraTag assay | met-HER2+ BCA (n = 89), T | ↑ High HER3 expression was associated with shorter PFS in initially metastatic HER2 + BCA |
Gori et al. [41] | IHC (RTJ1) | met-HER2+ BCA (n = 61), T | - HER3 was not significantly associated with clinical outcome in initially metastatic HER2 + BCA |
Han et al. [37] | VeraTag assay | met-HER2+ BCA (n = 50), T | ↓ High HER3 expression was related to longer TTP in advanced HER2 + BCA |
Larsen et al. [43] | IHC (DAK-H3-IC) | ER+ BCA (n = 1062) | - HER3 expression did not shown any association to DFS |
Chiu et al. [27] | IHC (Ab-10 pAb) | BCA (n = 3123) | ↑ High HER3 expression was associated with decreased BCSS |
Yonemori et al. [45] | IHC (DAK-H3-IC) | HER2+ BCA (n = 44), neoAdj.T | - HER3 expression did not significantly correlate with pCR |
Giltnane et al. [28] | AQUA | BCA (n = 550) | ↑ High HER3 expression was associated with decreased survival |
Haas et al. [42] | IHC (SGP1) | HER2- BCA (n = 171) | - No prognostic value for HER3 |
Sassen et al. [50] | IHC (5A12), FISH | BCA (n = 173) | - No prognostic value for HER3 expression, HER3 gene amplification was related to decreased DFS |
Giuliani et al. [52] | IHC (RTJ1) | met-HER2+ BCA (n = 103), T | - No prognostic value for HER3 |
Lee et al. [36] | IHC (pAb) | BCA (n = 378) | ↓ High HER3 expression correlated with longer DFS |
Bianchi et al. [53] | IHC (RTJ1) | BCA (n = 145) | - No prognostic value for HER3 expression singly, but high co-expression of HER2/3/4 predicted worse prognosis |
Fuchs et al. [34] | IHC (C-17 pAb) | BCA (n = 48) | ↑ High HER3 expression singly and in co-expression with high HER1 and HER2 was associated with poor prognosis |
Robinson et al. [32] | IHC (polyclonal) | met-HER2+ BCA (n = 104), T | ↑ High HER3 expression was associated with worse OS |
Wiseman et al. [33] | IHC (2-18C9) | BCA (n = 242) | ↑ High HER3 expression independently and with high HER1 and/or HER2 was associated with decreased DSS |
Abd El-Rehim et al. [15] | IHC (RTJ1) | BCA (n = 1499) | - No prognostic value for HER3 singly, but in co-expression with high HER2 predicted unfavorable DFS and OS |
Smith et al. [49] | IHC | met-HER2+ BCA (n = 77), T | - No prognostic value for HER3 |
Bièche et al. [35] | qRT-PCR | BCA (n = 130) | ↑ High HER3 mRNA was associated with shorten RFS |
Witton et al. [30] | IHC (H3.105.5) | BCA (n = 220) | ↑ High HER3 expression was associated with reduced BCSS survival |
Suo et al. [47] | IHC (sc-415), RT-PCR | BCA (n = 100) | - High HER3 expression was predictive for reduced DFS or BCSS only in co-overexpression with HER2 or HER1 + HER2 |
Pawlowski et al. [40] | qRT-PCR | BCA (n = 365) | ↓ Elevated HER3 mRNA expression was associated with a better prognosis in terms of OS, but did not relate to RFS |
Travis et al. [46] | IHC (RTJ1) | BCA (n = 346), met-BCA (n = 145) | - No prognostic value for HER3 expression neither in primary nor metastatic breast cancer |
Lemoine et al. [51] | IHC (49.3 pAb) | BCA (n = 195) | - No demonstrable relationship between HER3 expression and survival |